Refine
Year of publication
Document Type
- Article (332) (remove)
Has Fulltext
- yes (332)
Is part of the Bibliography
- no (332)
Keywords
- e +-e − Experiments (11)
- BESIII (10)
- Hadron-Hadron Scattering (8)
- Branching fraction (7)
- Heavy Ion Experiments (7)
- Quarkonium (6)
- Particle and Resonance Production (5)
- Collective Flow (4)
- Electroweak interaction (4)
- Exotics (4)
Institute
By analyzing an electron-positron collision data sample corresponding to an integrated luminosity of 2.93 fb−1 taken at the center-of-mass energy of 3.773 GeV with the BESIII detector, we obtain for the first time the absolute branching fractions for seven 𝐷0 and 𝐷+ hadronic decay modes and search for the hadronic decay 𝐷0→𝐾0𝑆𝐾0𝑆𝜋0 with much improved sensitivity. The results are ℬ(𝐷0→𝐾0𝑆𝜋0𝜋0𝜋0)=(7.64±0.30±0.29)×10−3, (𝐷0→𝐾−𝜋+𝜋0𝜋0𝜋0)=9.54±0.30±0.31)×10−3, ℬ(𝐷0→𝐾0𝑆𝜋+𝜋−𝜋0𝜋0)=(12.66±0.45±0.43)×10−3, ℬ(𝐷+→𝐾0𝑆𝜋+𝜋0𝜋0)=(29.04±0.62±0.87)×10−3, ℬ(𝐷+→𝐾0𝑆𝜋+𝜋+𝜋−𝜋0)=(15.28±0.57±0.60)×10−3, ℬ(𝐷+→𝐾0𝑆𝜋+𝜋0𝜋0𝜋0)=(5.54±0.44±0.32)×10−3, ℬ(𝐷+→𝐾−𝜋+𝜋+𝜋0𝜋0)=(4.95±0.26±0.19)×10−3, and ℬ(𝐷0→𝐾0𝑆𝐾0𝑆𝜋0)<1.45×10−4 at the 90% confidence level. Here, the first uncertainties are statistical, and the second ones are systematic. The newly studied decays greatly enrich the knowledge of the 𝐷→¯𝐾𝜋𝜋𝜋 and 𝐷→¯𝐾𝜋𝜋𝜋𝜋 hadronic decays and open a bridge to access more two-body hadronic 𝐷 decays containing scalar, vector, axial, and tensor mesons in the charm sector.
Utilizing the data set corresponding to an integrated luminosity of 3.19 fb−1 collected by the BESIII detector at a center-of-mass energy of 4.178 GeV, we perform an amplitude analysis of the 𝐷+
𝑠→𝜋+𝜋−𝜋+ decay. The sample contains 13,797 candidates with a signal purity of ∼80%. The amplitude and phase of the contributing 𝜋𝜋 𝒮 wave are measured based on a quasi-model-independent approach, along with the amplitudes and phases of the 𝒫 and 𝒟 waves parametrized by Breit-Wigner models. The fit fractions of different intermediate decay channels are also reported.
Using inclusive decays of the J/ψ, a precise determination of the number of J/ψ events collected with the BESIII detector is performed. For the two data sets taken in 2009 and 2012, the numbers of J/ψ events are recalculated to be (224.0±1.3)×106 and (1088.5±4.4)×106 respectively, which are in good agreement with the previous measurements. For the J/ψ sample taken in 2017--2019, the number of events is determined to be (8774.0±39.4)×106. The total number of J/ψ events collected with the BESIII detector is determined to be (10087±44)×106, where the uncertainty is dominated by systematic effects and the statistical uncertainty is negligible.
Based on (10087±44)×106 𝐽/𝜓 events collected with the BESIII detector at BEPCII, the double Dalitz decay 𝜂′→𝑒+𝑒−𝑒+𝑒− is observed for the first time via the 𝐽/𝜓→𝛾𝜂′ decay process. The significance is found to be 5.7𝜎 with systematic uncertainties taken into consideration. Its branching fraction is determined to be ℬ(𝜂′→𝑒+𝑒−𝑒+𝑒−)=(4.5±1.0(stat)±0.5(sys))×10−6.
The singly Cabibbo-suppressed decay D+s → K+π+π−π0 is observed by using a data set corresponding to an integrated luminosity of 6.32 fb−1 recorded by the BESIII detector at the centre-of-mass energies between 4.178 and 4.226 GeV. The first amplitude analysis of D+s → K+π+π−π0 reveals the sub-structures in this decay and determines the fractions and relative phases of different intermediate processes. The dominant intermediate process is D+s → K∗0ρ+, with a fit fraction of (40.5 ± 2.8stat. ± 1.5syst.)%. With the detection efficiency based on our amplitude analysis, the absolute branching fraction forD+s → K+π+π−π0 is measured to be (9.75 ± 0.54stat. ± 0.17syst.) × 10−3.
Using (448.1 ± 2.9) × 106 ψ(3686) events collected with the BESIII detector at the BEPCII collider, the decay ψ(3686) → Σ⁻Σ‾⁺ is observed for the first time with a branching fraction of (2.82 ± 0.04stat. ± 0.08syst.) × 10−4, and the angular parameter αΣ− is measured to be 0.96 ± 0.09stat. ± 0.03syst..
A measurement of the 𝐶𝑃-even fraction of the decay 𝐷0→𝜋+𝜋−𝜋+𝜋− is performed with a quantum-correlated 𝜓(3770)→𝐷¯𝐷 data sample collected by the BESIII experiment, corresponding to an integrated luminosity of 2.93 fb−1. Using a combination of 𝐶𝑃 eigenstates, 𝐷→𝜋+𝜋−𝜋0 and 𝐷→𝐾0𝑆,𝐿𝜋+𝜋− as tagging modes, the 𝐶𝑃-even fraction is measured to be 𝐹4𝜋+=0.735±0.015±0.005, where the first uncertainty is statistical and the second is systematic. This is the most precise determination of this quantity to date. It provides valuable model-independent input for the measurement of the angle 𝛾 of the Cabibbo-Kobayashi-Maskawa matrix with 𝐵±→𝐷𝐾± decays, and for time-dependent studies of 𝐶𝑃 violation and mixing in the 𝐷0−¯𝐷0 system.
Using a sample of about 1010 𝐽/𝜓 events collected at a center-of-mass energy √𝑠=3.097 GeV with the BESIII detector, the electromagnetic Dalitz decays 𝐽/𝜓→𝑒+𝑒−𝜋+𝜋−𝜂′, with 𝜂′→𝛾𝜋+𝜋− and 𝜂′→𝜋+𝜋−𝜂, have been studied. The decay 𝐽/𝜓→𝑒+𝑒−𝑋(1835) is observed with a significance of 15𝜎, and also an 𝑒+𝑒− invariant-mass dependent transition form factor of 𝐽/𝜓→𝑒+𝑒−𝑋(1835) is presented for the first time. The intermediate states 𝑋(2120) and 𝑋(2370) are also observed in the 𝜋+𝜋−𝜂′ invariant-mass spectrum with significances of 5.3𝜎 and 7.3𝜎. The corresponding product branching fractions for 𝐽/𝜓→𝑒+𝑒−𝑋, 𝑋→𝜋+𝜋−𝜂′ [𝑋=𝑋(1835), 𝑋(2120), and 𝑋(2370)] are reported.
The long-term effect of protection by two doses of SARS-CoV-2 vaccination in patients receiving chronic intermittent hemodialysis (CIHD) is an urging question. We investigated the humoral and cellular immune response of 42 CIHD patients who had received two doses of SARS-CoV-2 vaccine, and again after a booster vaccine with mRNA-1273 six months later. We measured antibody levels and SARS-CoV-2-specific surrogate neutralizing antibodies (SNA). Functional T cell immune response to vaccination was assessed by quantifying interferon-γ (IFN-γ) and IL-2 secreting T cells specific for SARS-CoV-2 using an ELISpot assay. Our data reveal a moderate immune response after the second dose of vaccination, with significantly decreasing SARS-CoV-2-specific antibody levels and less than half of the study group showed neutralizing antibodies six months afterwards. Booster vaccines increased the humoral response dramatically and led to a response rate of 89.2% for antibody levels and a response rate of 94.6% for SNA. Measurement in a no response/low response (NR/LR) subgroup of our cohort, which differed from the whole group in age and rate of immunosuppressive drugs, indicated failure of a corresponding T cell response after the booster vaccine. We strongly argue in favor of a regular testing of surrogate neutralizing antibodies and consecutive booster vaccinations for CIHD patients to provide a stronger and persistent immunity.
Despite the recent availability of vaccines against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 drugs. Monoclonal neutralizing antibodies are an important drug class in the global fight against the SARS-CoV-2 pandemic due to their ability to convey immediate protection and their potential to be used as both prophylactic and therapeutic drugs. Clinically used neutralizing antibodies against respiratory viruses are currently injected intravenously, which can lead to suboptimal pulmonary bioavailability and thus to a lower effectiveness. Here we describe DZIF-10c, a fully human monoclonal neutralizing antibody that binds the receptor-binding domain of the SARS-CoV-2 spike protein. DZIF-10c displays an exceptionally high neutralizing potency against SARS-CoV-2, retains full activity against the variant of concern (VOC) B.1.1.7 and still neutralizes the VOC B.1.351, although with reduced potency. Importantly, not only systemic but also intranasal application of DZIF-10c abolished the presence of infectious particles in the lungs of SARS-CoV-2 infected mice and mitigated lung pathology when administered prophylactically. Along with a favorable pharmacokinetic profile, these results highlight DZIF-10c as a novel human SARS-CoV-2 neutralizing antibody with high in vitro and in vivo antiviral potency. The successful intranasal application of DZIF-10c paves the way for clinical trials investigating topical delivery of anti-SARS-CoV-2 antibodies.